welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian Eye 2020.
Additionally, this treatment would target the long-term manifestations of the disease rather than the short-term manifestations that are primarily targeted with steroids and other second line agents, he said.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
¿Qué Es La Enfermedad De Graves?¿De Qué Manera Afecta A Los Ojos La En...
Thyroid Eye Disease: The Battle of the Bulge, Part IIhttps://www.youtube.com/watch?v=S9H6V-sO...
Graves’ OrbitopathyEpidemiology: Eye complications occur i...
Death by Suicide in Graves’ Disease and Graves’ Orbitopathy: A Nationwide Danish Register StudyBackground: Graves' disease (GD) is ass...
Teprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid eye D...Thyroid eye disease is a disabling autoi...
Graves’ Orbitopathy as a Rare Disease in Europe: A European Group on Graves’ Orbitopathy (EUGOGO) Positi...Background: Graves' orbitopathy (GO) is...
The Medical University of South Carolina Health Graves’ Eye Disease ClinicThe Medical University of South Carolina...